Answers are grounded in this paper and cite their sources.
Peptidyl-arginine deiminase (PAD) family enzymes are pivotal enzymes that catalyze the citrullination of arginine in substrate proteins. Elevated levels of citrullinated proteins are tightly linked to the incidence of rheumatoid arthritis, neurodegenerative diseases, and cancers, thus highlighting PAD enzymes as important therapeutic targets. Although several PAD isozyme-selective and non-selective small molecule inhibitors have been reported over the last decade, it remains important to identify distinct ligands that may offer differentiated therapeutic potential or selectivity. Herein, we present a PAD4-selective inhibitor identified through a structure-based virtual screen, which binds to a distinct site from known inhibitors. Biochemical and biophysical characterizations show that the inhibitor is selective for PAD4 over PAD1/PAD2/PAD3 via targeting the orthosteric site preferably at low calcium concentrations. A co-crystal structure of the inhibitor-bound PAD4 shows that the inhibitor binds to an unprecedented pocket near the catalytic site present at low calcium concentrations and stabilizes the catalytically inactive conformation. Owing to its distinctive binding site, this inhibitor series is designated as “Orthosteric B inhibitors”. Structural analysis suggests a unique conformational plasticity of the PAD4 catalytic module, which may help rationalize the PAD4 selectivity of Orthosteric B inhibitors. Further structure-based drug design and computational approaches enabled optimization of the hit to afford a potent PAD4 inhibitor capable of blocking PAD4-mediated protein citrullination in human neutrophils.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: